LONDON, September 11, 2012 /PRNewswire/ --
A new report by visiongain assesses prospects for the leading 20 biopharma companies worldwide. Top pharmaceutical companies have consolidated their hold on the market by buying up most of the leading biotech products and platforms, according to Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022, published in September 2012.
Visiongain's study predicts revenues to 2022 for the leading companies and discusses their prospects. Roche continues to lead the market via its Genentech-developed biologics portfolio, but other multinationals are following. Top 10 players, according to the report's analysis, include Sanofi, which acquired Genzyme, GlaxoSmithKline, which this summer completed a takeover of Human Genome Sciences, and Pfizer, which bought Wyeth in 2009 to expand its capacities in vaccines and biologics.
Dr James Evans, a pharmaceutical industry analyst in visiongain, said: "The pharmaceutical industry is continuing to absorb the healthcare biotech industry. Amgen is still an independent biotech, but it is diversifying into generics, so the distinction between the two types of companies is being eroded from both sides. With biologics set to be the first, second and third bestselling pharmaceuticals of 2012, the competition for the biologics market is intense, and the coming of biosimilars is going to make it fiercer, by lowering the entry barriers for developing a biological drug.
"The biologics market is growing faster than the broader pharmaceutical market, and growth rates will be sustained through to 2022, our analyses show. Newer biological formats such as antibody-drug conjugates, therapeutic vaccines and cellular therapies will compensate for slowdown and contraction in areas such as erythropoietin and interferons. There will be hot competition in insulins, recombinant coagulating factors and mAbs, as companies battle for these lucrative market areas."
That new report forecasts that the biologics market will continue to expand rapidly to 2022, with leading pharma companies increasingly basing their growth strategies on opportunities in the biologics sector.
Visiongain is a business information provider based in London, UK. Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022 adds to that company's range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the visiongain report Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022 please visit http://www.visiongain.com/Report/889/Pharma-Leader-Series-Top-20-Biological-Drug-Manufacturers-2012-2022
For an executive summary of this report please email:
Sara Peerun at firstname.lastname@example.org
Notes for Editors
Companies listed in this report include:
Bristol-Myers Squibb (BMS)
Cambridge Antibody Technologies
Centocor Ortho Biotech
Chinese Academy of Medical Sciences
Chinese Academy of Sciences
Hoechst Marion Roussel
HudsonAlpha Institute for Biotechnology
Human Genome Sciences
Institute for Genomic Research
International Vaccine Institute
Jiangsu Walvax Biotech Company
Johns Hopkins University
Johnson & Johnson
Kyowa Hakko Kirin
Ludwig Institute for Cancer Research
Merck & Co.
Mitsubishi Tanabe Pharma
Mustafa Nevzat Pharmaceuticals
National Center for Drug Screening (China)
Pasteur Merieux Serums & Vaccins
Sabin Vaccine Institute
Sanofi Pasteur MSD
Sanwa Kagaku Kenkyusho
Shanghai Institute of Biological Sciences
Shanghai Institute of Materia Medica
Swedish Orphan Biovitrum
Synovis Life Technologies
Teva Pharmaceutical Industries
Tianjin Medical University Cancer Hospital
University of Queensland
Walter Reed Army Institute
World Health Organization (WHO)
Visiongain is one of the fastest growing and most innovative independent business intelligence companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters and management reports focusing on the Energy, Telecoms, Pharmaceuticals, Defence, Aviation and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44(0)207-336-6100